molsidomine has been researched along with Impotence in 13 studies
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Different studies on the performance of the direct NO donor linsidomine chlorhydrate (SIN-1) in patients with erectile dysfunction have had conflicting results." | 9.07 | Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction. ( Klän, R; Knispel, HH; Meier, T; Miller, K; Wegner, HE, 1994) |
| "Recently, nitric oxide was shown to be a mediator of penile erection in men and the nitric oxide donor linsidomine chlorhydrate (SIN-1) was introduced as a novel treatment option in patients with erectile dysfunction." | 9.07 | Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. ( Becker, AJ; Djamilian, MH; Jonas, U; Stief, CG; Truss, MC, 1994) |
| " Different studies on the performance of the direct NO-donor linsidomine chlorhydrate (SIN-1) in patients with erectile dysfunction have come to conflicting results ranging from highest praise to complete dismissal." | 8.79 | Nitric oxide donor, linsidomine chlorhydrate (SIN-1), in the diagnosis and treatment of erectile dysfunction: critical appraisal and review of the literature. ( Klän, R; Knispel, HH; Meier, T; Miller, K; Wegner, HE, 1995) |
| "The results highlight the rationale behind the repositioning of molsidomine therapy for the management of diabetic erectile dysfunction." | 7.88 | Repositioning of molsidomine for its efficacy in diabetes induced erectile dysfunction in rats: In silico, in vitro and in vivo approach. ( Minaz, N; Pathak, L; Razdan, R, 2018) |
| " Since nitric oxide seems to account for the biological actions of endothelium derived relaxing factor, a study was done to examine a possible role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the treatment of erectile dysfunction." | 7.68 | Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction. ( Andersson, KE; Djamilian, M; Holmquist, F; Jonas, U; Krah, H; Stief, CG, 1992) |
| "SIN-1 is not superior to PGE1 in the treatment of erectile dysfunction caused by venous leakage, and failure of NO-mediated smooth muscle relaxation does not play a part in the entity, "venous leakage." | 5.29 | Effect of nitric oxide-donor, linsidomine chlorhydrate, in treatment of human erectile dysfunction caused by venous leakage. ( Knispel, HH; Wegner, HE, 1993) |
| " Different studies on the performance of the direct NO donor linsidomine chlorhydrate (SIN-1) in patients with erectile dysfunction have had conflicting results." | 5.07 | Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction. ( Klän, R; Knispel, HH; Meier, T; Miller, K; Wegner, HE, 1994) |
| "Recently, nitric oxide was shown to be a mediator of penile erection in men and the nitric oxide donor linsidomine chlorhydrate (SIN-1) was introduced as a novel treatment option in patients with erectile dysfunction." | 5.07 | Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. ( Becker, AJ; Djamilian, MH; Jonas, U; Stief, CG; Truss, MC, 1994) |
| " Different studies on the performance of the direct NO-donor linsidomine chlorhydrate (SIN-1) in patients with erectile dysfunction have come to conflicting results ranging from highest praise to complete dismissal." | 4.79 | Nitric oxide donor, linsidomine chlorhydrate (SIN-1), in the diagnosis and treatment of erectile dysfunction: critical appraisal and review of the literature. ( Klän, R; Knispel, HH; Meier, T; Miller, K; Wegner, HE, 1995) |
| "The results highlight the rationale behind the repositioning of molsidomine therapy for the management of diabetic erectile dysfunction." | 3.88 | Repositioning of molsidomine for its efficacy in diabetes induced erectile dysfunction in rats: In silico, in vitro and in vivo approach. ( Minaz, N; Pathak, L; Razdan, R, 2018) |
| "Linsidomine induced complete rigidity in 4 subjects considered to suffer from psychogenic impotence (versus 11 subjects with PGE1) and 1 subject considered to suffer from arterial disease (versus 8 subjects with PGE1)." | 3.70 | [Erectile response to intracavernous injection of linsidomine in 38 impotent patients. Comparison with prostaglandin E1]. ( Buvat, J; Lemaire, A, 1998) |
| " Since nitric oxide seems to account for the biological actions of endothelium derived relaxing factor, a study was done to examine a possible role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the treatment of erectile dysfunction." | 3.68 | Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction. ( Andersson, KE; Djamilian, M; Holmquist, F; Jonas, U; Krah, H; Stief, CG, 1992) |
| "SIN-1 is not superior to PGE1 in the treatment of erectile dysfunction caused by venous leakage, and failure of NO-mediated smooth muscle relaxation does not play a part in the entity, "venous leakage." | 1.29 | Effect of nitric oxide-donor, linsidomine chlorhydrate, in treatment of human erectile dysfunction caused by venous leakage. ( Knispel, HH; Wegner, HE, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (76.92) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Minaz, N | 1 |
| Razdan, R | 1 |
| Pathak, L | 1 |
| Machtens, S | 1 |
| Ckert, S | 1 |
| Stief, CG | 4 |
| Tsikas, D | 1 |
| Frlich, Jr | 1 |
| Jonas, U | 4 |
| Porst, H | 2 |
| Wegner, HE | 3 |
| Knispel, HH | 3 |
| Klän, R | 2 |
| Meier, T | 2 |
| Miller, K | 2 |
| Truss, MC | 2 |
| Becker, AJ | 1 |
| Djamilian, MH | 1 |
| Schultheiss, D | 1 |
| Lemaire, A | 1 |
| Buvat, J | 1 |
| Maisch, B | 1 |
| Holmquist, F | 1 |
| Djamilian, M | 1 |
| Krah, H | 1 |
| Andersson, KE | 1 |
2 reviews available for molsidomine and Impotence
| Article | Year |
|---|---|
Nitric oxide donor, linsidomine chlorhydrate (SIN-1), in the diagnosis and treatment of erectile dysfunction: critical appraisal and review of the literature.
Topics: Animals; Erectile Dysfunction; Humans; Male; Molsidomine; Vasodilator Agents | 1995 |
[Pharmacological therapy in erectile dysfunction--current standards and new viewpoint].
Topics: Alprostadil; Dosage Forms; Enzyme Inhibitors; Erectile Dysfunction; Humans; Male; Molsidomine; Muscl | 1997 |
3 trials available for molsidomine and Impotence
| Article | Year |
|---|---|
Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Alprostadil; Cross-Over Studies; Erectile Dysfunction; Humans; Male; | 1994 |
Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction.
Topics: Adult; Aged; Drug Therapy, Combination; Electromyography; Erectile Dysfunction; Follow-Up Studies; H | 1994 |
Prostaglandin E1 and the nitric oxide donor linsidomine for erectile failure: a diagnostic comparative study of 40 patients.
Topics: Adult; Aged; Alprostadil; Blood Flow Velocity; Erectile Dysfunction; Humans; Male; Middle Aged; Mols | 1993 |
8 other studies available for molsidomine and Impotence
| Article | Year |
|---|---|
Repositioning of molsidomine for its efficacy in diabetes induced erectile dysfunction in rats: In silico, in vitro and in vivo approach.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Diabetes Mellitus, Experimental; Drug Repositioning | 2018 |
Effects of various nitric oxide-donating drugs on adrenergic tension of human seminal vesicles in vitro.
Topics: Adrenergic alpha-Agonists; Aged; Colforsin; Cyclic GMP; Ejaculation; Erectile Dysfunction; Humans; I | 2003 |
The rationale for prostaglandin E1 (alpha-alprostadil) in the management of male impotence.
Topics: Alprostadil; Erectile Dysfunction; Humans; Impotence, Vasculogenic; Male; Molsidomine; Moxisylyte; P | 1995 |
Effect of nitric oxide-donor, linsidomine chlorhydrate, in treatment of human erectile dysfunction caused by venous leakage.
Topics: Adult; Aged; Alprostadil; Erectile Dysfunction; Humans; Male; Middle Aged; Molsidomine; Nitric Oxide | 1993 |
[Erectile response to intracavernous injection of linsidomine in 38 impotent patients. Comparison with prostaglandin E1].
Topics: Adult; Aged; Alprostadil; Data Interpretation, Statistical; Erectile Dysfunction; Humans; Impotence, | 1998 |
[Therapy recommendations for adverse effects of Viagra and nitrates (NO-donors)].
Topics: Angina Pectoris; Blood Pressure; Contraindications; Drug Therapy, Combination; Erectile Dysfunction; | 1998 |
[Erectile dysfunction. Help also for cardiac patients].
Topics: Apomorphine; Contraindications; Coronary Disease; Drug Interactions; Erectile Dysfunction; Humans; M | 2001 |
Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction.
Topics: Blood Flow Velocity; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Male; Molsidomi | 1992 |